About
About China Resources Pharmaceutical Group Limited
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular, metabolism, intravenous infusion, and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operating retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, Kun Zhong Yao, and Tasly to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited operates as a subsidiary of CRH (Pharmaceutical) Limited.
Visit company website
5 years, 5 months ago
China Resources Pharmaceutical Group Limited is currently in a long term downtrend where the price is trading 0.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.2.
China Resources Pharmaceutical Group Limited's total revenue rose by 8.3% to $111B since the same quarter in the previous year.
Its net income has increased by 186.8% to $720M since the same quarter in the previous year.
Finally, its free cash flow fell by 99.9% to $6M since the same quarter in the previous year.
Based on the above factors, China Resources Pharmaceutical Group Limited gets an overall score of 3/5.